vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and TELA Bio, Inc. (TELA). Click either name above to swap in a different company.

TELA Bio, Inc. is the larger business by last-quarter revenue ($20.9M vs $19.2M, roughly 1.1× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -43.3%, a 23.6% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs 18.2%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-5.0M). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs 12.1%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

TELA Bio, Inc. is a medical technology company focused on developing and commercializing innovative soft tissue repair solutions for surgical procedures. Its core product portfolio targets applications including hernia repair, abdominal wall reconstruction and other general surgery use cases, serving hospitals, ambulatory surgical centers and healthcare providers primarily across the United States and select global markets.

CURI vs TELA — Head-to-Head

Bigger by revenue
TELA
TELA
1.1× larger
TELA
$20.9M
$19.2M
CURI
Growing faster (revenue YoY)
CURI
CURI
+17.6% gap
CURI
35.8%
18.2%
TELA
Higher net margin
CURI
CURI
23.6% more per $
CURI
-19.7%
-43.3%
TELA
More free cash flow
CURI
CURI
$8.9M more FCF
CURI
$3.9M
$-5.0M
TELA
Faster 2-yr revenue CAGR
CURI
CURI
Annualised
CURI
26.5%
12.1%
TELA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
TELA
TELA
Revenue
$19.2M
$20.9M
Net Profit
$-3.8M
$-9.0M
Gross Margin
65.9%
Operating Margin
-17.6%
-31.9%
Net Margin
-19.7%
-43.3%
Revenue YoY
35.8%
18.2%
Net Profit YoY
-34.6%
1.8%
EPS (diluted)
$-0.07
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
TELA
TELA
Q4 25
$19.2M
$20.9M
Q3 25
$18.4M
$20.7M
Q2 25
$19.0M
$20.2M
Q1 25
$15.1M
$18.5M
Q4 24
$14.1M
$17.6M
Q3 24
$12.6M
$19.0M
Q2 24
$12.4M
$16.1M
Q1 24
$12.0M
$16.6M
Net Profit
CURI
CURI
TELA
TELA
Q4 25
$-3.8M
$-9.0M
Q3 25
$-3.7M
$-8.6M
Q2 25
$784.0K
$-9.9M
Q1 25
$319.0K
$-11.3M
Q4 24
$-2.8M
$-9.2M
Q3 24
$-3.1M
$-10.4M
Q2 24
$-2.0M
$-12.6M
Q1 24
$-5.0M
$-5.7M
Gross Margin
CURI
CURI
TELA
TELA
Q4 25
65.9%
Q3 25
67.5%
Q2 25
69.8%
Q1 25
67.6%
Q4 24
63.6%
Q3 24
67.8%
Q2 24
68.8%
Q1 24
68.3%
Operating Margin
CURI
CURI
TELA
TELA
Q4 25
-17.6%
-31.9%
Q3 25
-24.5%
-36.5%
Q2 25
2.5%
-45.0%
Q1 25
0.5%
-56.5%
Q4 24
-27.4%
-47.3%
Q3 24
-25.8%
-49.4%
Q2 24
-20.6%
-71.9%
Q1 24
-30.4%
-29.1%
Net Margin
CURI
CURI
TELA
TELA
Q4 25
-19.7%
-43.3%
Q3 25
-20.4%
-41.6%
Q2 25
4.1%
-49.1%
Q1 25
2.1%
-60.8%
Q4 24
-19.9%
-52.2%
Q3 24
-24.3%
-54.7%
Q2 24
-16.4%
-78.3%
Q1 24
-42.0%
-34.1%
EPS (diluted)
CURI
CURI
TELA
TELA
Q4 25
$-0.07
$-0.17
Q3 25
$-0.06
$-0.19
Q2 25
$0.01
$-0.22
Q1 25
$0.01
$-0.25
Q4 24
$-0.05
$-0.17
Q3 24
$-0.06
$-0.42
Q2 24
$-0.04
$-0.51
Q1 24
$-0.09
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
TELA
TELA
Cash + ST InvestmentsLiquidity on hand
$27.3M
$50.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$6.3M
Total Assets
$75.7M
$81.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
TELA
TELA
Q4 25
$27.3M
$50.8M
Q3 25
$27.8M
$29.7M
Q2 25
$28.1M
$35.0M
Q1 25
$33.4M
$42.8M
Q4 24
$32.1M
$52.7M
Q3 24
$33.2M
$17.3M
Q2 24
$39.5M
$26.5M
Q1 24
$38.8M
$37.1M
Total Debt
CURI
CURI
TELA
TELA
Q4 25
Q3 25
Q2 25
$41.4M
Q1 25
$41.3M
Q4 24
$41.1M
Q3 24
$41.0M
Q2 24
$40.8M
Q1 24
$40.7M
Stockholders' Equity
CURI
CURI
TELA
TELA
Q4 25
$41.5M
$6.3M
Q3 25
$47.2M
$1.6M
Q2 25
$49.8M
$9.2M
Q1 25
$58.1M
$18.1M
Q4 24
$57.8M
$28.5M
Q3 24
$62.2M
$-6.3M
Q2 24
$64.8M
$2.9M
Q1 24
$67.0M
$14.4M
Total Assets
CURI
CURI
TELA
TELA
Q4 25
$75.7M
$81.4M
Q3 25
$74.7M
$61.6M
Q2 25
$78.7M
$67.5M
Q1 25
$85.3M
$77.3M
Q4 24
$86.2M
$86.6M
Q3 24
$87.6M
$53.0M
Q2 24
$90.9M
$60.2M
Q1 24
$94.6M
$71.8M
Debt / Equity
CURI
CURI
TELA
TELA
Q4 25
Q3 25
Q2 25
4.51×
Q1 25
2.28×
Q4 24
1.45×
Q3 24
Q2 24
14.22×
Q1 24
2.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
TELA
TELA
Operating Cash FlowLast quarter
$4.0M
$-4.9M
Free Cash FlowOCF − Capex
$3.9M
$-5.0M
FCF MarginFCF / Revenue
20.5%
-23.8%
Capex IntensityCapex / Revenue
0.1%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-28.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
TELA
TELA
Q4 25
$4.0M
$-4.9M
Q3 25
$4.4M
$-5.7M
Q2 25
$2.8M
$-7.9M
Q1 25
$1.9M
$-9.7M
Q4 24
$3.0M
$-7.5M
Q3 24
$2.3M
$-9.0M
Q2 24
$2.2M
$-10.7M
Q1 24
$666.0K
$-14.4M
Free Cash Flow
CURI
CURI
TELA
TELA
Q4 25
$3.9M
$-5.0M
Q3 25
$-5.9M
Q2 25
$-8.0M
Q1 25
$1.8M
$-9.8M
Q4 24
$-7.8M
Q3 24
$-9.1M
Q2 24
$-11.0M
Q1 24
$-14.7M
FCF Margin
CURI
CURI
TELA
TELA
Q4 25
20.5%
-23.8%
Q3 25
-28.7%
Q2 25
-39.7%
Q1 25
12.2%
-52.7%
Q4 24
-44.2%
Q3 24
-48.0%
Q2 24
-68.3%
Q1 24
-88.5%
Capex Intensity
CURI
CURI
TELA
TELA
Q4 25
0.1%
0.4%
Q3 25
0.0%
1.0%
Q2 25
0.0%
0.6%
Q1 25
0.5%
0.2%
Q4 24
0.0%
1.5%
Q3 24
0.0%
0.6%
Q2 24
0.0%
1.9%
Q1 24
0.0%
1.8%
Cash Conversion
CURI
CURI
TELA
TELA
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CURI
CURI

Segment breakdown not available.

TELA
TELA

Ovitex$13.4M64%
Ovitex Prs$6.8M33%
Other$597.0K3%

Related Comparisons